Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex for Neuroprotection in Huntington's Disease
NCT01502046Phase 2Completed
- Start
- Sep 2011
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cannabidiol in Huntington's disease (HD). Started Sep 2011; status: completed.
02
Drugs
cannabidiol
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT01502046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01502046.